VivoSim Labs, Inc. (VIVS) Investor Relations Documents

VivoSim Labs, Inc. (VIVS) investor relations documents from the company's IR site: 16 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-06Press releaseVivoSim Provides Financial and Listing Compliance Update
2026-07-21Press releaseVivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
2026-07-16Press releaseVivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Health
2026-07-15Press releaseVivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY20
2026-06-29Press releaseVivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting
2026-04-28Press releaseVivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results
2026-04-01Press releaseVivoSim Announces Pricing of up to a $4 Million Public Offering
2026-03-24Press releaseVivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs
2026-03-03Press releaseVivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales
2026-02-11Press releaseVivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicol
Press releaseRead More >>
Press releaseRead More >>
Press releaseRead More >>
Press releaseRead More >>
Press releaseRead More >>
Press releaseRead More >>

VIVS overview · VIVS earnings · VIVS financials · VIVS KPIs · VIVS ownership · VIVS peers · VIVS filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.